By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
October 31, 2025 4:39 AM EDT
Medical Herald
Search
  • Health Conditions
    Health ConditionsShow More
    Beware of Counterfeit Weight Loss Drugs Sold Online
    Weight Management
    Father’s Back Pain Leads to Tragic Cancer Diagnosis
    Cancer
    Novo Nordisk’s CEO Emphasizes Strategic Risks to Lead Obesity Market
    Weight Management
    Medtronic Launches Ankle Implant for Bladder Control
    Health Conditions
    Stewart’s Caring Place Highlights All Cancer Awareness in October
    Breast Cancer
  • Wellness & Self-Care
    Wellness & Self-CareShow More
    Pureance HydraLift: A Scientific Approach to Hair Care
    Wellness & Self-Care
    Jewel Reflects on Fame and Mental Health Advocacy Journey
    Mental Health
    Discover the Health Benefits of Hazelnuts
    Healthy Living
    How the Government Shutdown Affects Health Insurance Costs
    Wellness & Self-Care
    NYC Sues Tech Giants Over Youth Mental Health Crisis
    Mental Health
  • Nutrition & Fitness
    Nutrition & FitnessShow More
    Delicious Roasted Salmon with Olives from Dan Pelosi
    Healthy Recipes
    Short Exercise Bursts: A New Trend in Fitness?
    Fitness
    PepsiCo Launches Protein-Focused Beverages to Meet Demand
    Diet & Nutrition
    Calcium Loaf: A Depression-Era Recipe for Today’s Food Challenges
    Healthy Recipes
    Effective Full-Body Workout Enhances Testosterone and Muscle
    Fitness
  • Innovation
    InnovationShow More
    Understanding Superspreading and Pathogen Virulence Evolution
    Innovation
    Starkey Launches Innovative AI Hearing Aid for All Generations
    Innovation
    AstraZeneca Boosts Virginia Investment to $4.5 Billion for Drug Production
    Drugs & Medications
    How ALV-J Virus Bypasses Immune Defense Using miR-155
    Innovation
    Nursing Homes’ Use of Painkillers and Antidepressants Raises Risks
    Drugs & Medications
  • News
    NewsShow More
    Diet Coke Lime Set to Return in 2025 After Seven-Year Hiatus
    News
    Dublin Environmentalists Celebrate Tentative Repeal of Measure II
    News
    Trust in CDC Plummets Under Kennedy’s Leadership, Poll Reveals
    News
    St. Joseph Plans New Community Center and Cannabis Dispensary
    News
    Harry and Meghan Shine at World Mental Health Day Gala in NYC
    News
Font ResizerAa
Medical HeraldMedical Herald
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Search
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Follow US
Copyright © 2025, Medical Herald. All Rights Reserved.
Home » News » Skye’s Obesity Drug Fails Key Mid-Stage Trial, Share Prices Plummet

Skye’s Obesity Drug Fails Key Mid-Stage Trial, Share Prices Plummet

By Ethan Granger
Published: October 9, 2025
Share

Skye has staked its future on nimacimab, a weekly subcutaneous injection specifically developed to combat obesity. This pivot comes after the company’s decision to cease the development of its eye disease drug candidate, which faltered during a mid-stage clinical trial last year.

Nimacimab works by blocking the CB1 protein, which plays a vital role in the body’s ability to break down stored fat and manage hormones related to appetite. This mechanism is designed to facilitate sustained weight loss while preserving muscle mass. Despite these promising attributes, the recent trial results have not met investors’ expectations, leading to a significant decrease in Skye’s stock value.

Analyst Kristen Kluska from Cantor expressed skepticism regarding the drug’s effectiveness based on the latest data, stating, “While we are still intrigued by Skye’s targeting approach of CB1, the bottom line is we aren’t convinced yet from the data reported today.” Kluska further emphasized that the company’s story remains a “show me story”; higher doses will be crucial to determine if nimacimab can achieve enough weight loss to compete effectively in the market.

In the recent trial, Skye reported that no neuropsychiatric issues, which have historically been linked to similar drugs, were detected with nimacimab. CEO Punit Dhillon reassured stakeholders, stating, “We have a solution on addressing the safety concern that’s kind of plagued the mechanism up until now.” This is a significant point, as past medications in this category have faced scrutiny over safety and adverse effects.

Additionally, the company highlighted that nimacimab demonstrated a unique advantage: it helped patients retain more lean body mass compared to semaglutide, a competing drug offered by Novo Nordisk. This factor could position nimacimab favorably in comparisons with existing obesity treatments.

Looking ahead, the combination of nimacimab with other agents, including Novo Nordisk and Eli Lilly’s medications, is projected to create substantial revenue potential. Industry experts estimate that these combined treatments could generate more than $30 billion in sales by 2035, offering a lucrative market opportunity if they pass subsequent trials.

Despite having a promising drug mechanism in nimacimab, Skye’s current challenges indicate that further research and development are essential to validate its efficacy and safety. The company’s commitment to addressing previous concerns surrounding neuropsychiatric effects may also play a crucial role in regaining investor confidence.

With the competitive landscape of obesity medications continuously evolving, Skye’s next moves will be critical. Investors and competitors alike will be watching how the company maneuvers through this trial setback as it strives to position nimacimab as a viable treatment option in an ever-growing market. As results emerge from ongoing studies, the viability of nimacimab will become clearer, and Skye will have to adapt its strategies accordingly to ensure its place in the future of obesity treatment.Drugs & Medications

Share This Article
Facebook LinkedIn Email Copy Link
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

HOT NEWS

Diet Coke Lime Set to Return in 2025 After Seven-Year Hiatus

October 30, 2025

Understanding Superspreading and Pathogen Virulence Evolution

Superspreading alters how pathogens evolve, influencing virulence, transmission, and long-term epidemic behavior across diverse host…

October 30, 2025

Dublin Environmentalists Celebrate Tentative Repeal of Measure II

A judge ruled Dublin must conduct an environmental review of Measure II, a controversial plan…

October 30, 2025

Delicious Roasted Salmon with Olives from Dan Pelosi

Dan Pelosi’s roasted salmon with Castelvetrano olives and orange zest blends freshness, simplicity, and flavor…

October 30, 2025

YOU MAY ALSO LIKE

Nando’s Limits Coca-Cola Refills Amid UK Sugar Crackdown

Nando’s limits free refills of sugary Coke, reflecting the UK’s push to cut sugar intake and tackle obesity through stronger…

October 13, 2025

Amy Schumer Talks Weight Loss Drugs and Social Media Buzz

Amy Schumer opens up about her weight loss journey, sharing her experience with medications and responding confidently to social media…

October 8, 2025

Ridgefield Schools Consider Stricter Cellphone Policies and Safety

Ridgefield parents push for tougher cellphone limits and enhanced school safety as the Board directs its Policy Committee to draft…

October 7, 2025

First West Nile Virus Death of the Season in Dallas County

Dallas County confirms its first West Nile Virus death of 2025. Health officials urge residents to stay alert and practice…

October 9, 2025

Medical Herald is your trusted source for medical news, scientific research, health policy updates, and expert insights from around the world. 

Category

  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
  • Privacy Policy
  • About Us
  • Contact

Follow US: 

  • Grow Big Agency Sites:
  • London Business Journal
Copyright © 2025, Medical Herald. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?